US EditionPregnancy vaccine reduces baby hospital admissions for RSV by 80%
Researchers found protection rose to 85% when the vaccine was given at least 4 weeks before birth, with stronger benefit in preterm infants.
- The study of nearly 300,000 babies in England found that infants born to mothers vaccinated at least two weeks before delivery had an 81.3% reduction in hospitalizations for severe RSV-related chest infections.
- Effectiveness was highest when the vaccine was administered at least four weeks before birth. However, even "late" doses—given just 10 to 13 days before delivery—still provided a 50% reduction in risk.
- Crucially, the vaccine was found to be highly effective for preterm infants, who are at the highest risk for severe bronchiolitis and pneumonia. For these babies, protection levels reached 69.4% if the mother was vaccinated at least 14 days prior to birth.
19 Articles
19 Articles
A vaccine administered during pregnancy, which protects newborns against bronchiolitis, is reducing hospital admissions of babies by more than 80%, states UK health authorities. Respiratory syncitial virus (RSV) infection is one of the leading causes of childhood hospitalization worldwide, and early childhood infection is associated with potential long-term effects, including recurrent wheezing or asthma, repeated hospital admissions and pulmona…
Maternal RSV vaccination cuts infant hospitalization risk by over 80%, major UKHSA study finds
The largest real-world study of its kind, presented today at ESCMID Global 2026, shows that maternal vaccination against respiratory syncytial virus (RSV) reduces the risk of hospitalisation in young infants by over 80% when given at least two weeks before birth.
Coverage Details
Bias Distribution
- 56% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
